3.64
price down icon5.21%   -0.20
after-market Handel nachbörslich: 3.72 0.08 +2.20%
loading

Absci Corp Aktie (ABSI) Neueste Nachrichten

pulisher
08:49 AM

Absci (NASDAQ:ABSI) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

08:49 AM
pulisher
08:00 AM

Absci’s ABS-201 stimulates human hair follicle growth ex vivo - BioWorld MedTech

08:00 AM
pulisher
Dec 11, 2025

Absci’s ABS-201 antibody shows promise for hair regrowth treatment - Investing.com

Dec 11, 2025
pulisher
Dec 11, 2025

Absci’s ABS-201 antibody shows promise for hair regrowth treatment By Investing.com - Investing.com Canada

Dec 11, 2025
pulisher
Dec 11, 2025

Absci Reports New Human Ex Vivo Data Demonstrating That - GlobeNewswire

Dec 11, 2025
pulisher
Dec 10, 2025

Is Absci Poised for a Surge? - StocksToTrade

Dec 10, 2025
pulisher
Dec 10, 2025

Absci, former U.S. soccer player Donovan announce partnership - TipRanks

Dec 10, 2025
pulisher
Dec 10, 2025

Absci Corporation Partners with Landon Donovan to Address Androgenetic Alopecia and Advance Therapeutic Innovations - Quiver Quantitative

Dec 10, 2025
pulisher
Dec 10, 2025

Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewswire

Dec 10, 2025
pulisher
Dec 10, 2025

Absci (NASDAQ:ABSI) Transforms Biotechnology With AI Integration - Kalkine Media

Dec 10, 2025
pulisher
Dec 09, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Dec 09, 2025
pulisher
Dec 05, 2025

Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine? - simplywall.st

Dec 05, 2025
pulisher
Dec 05, 2025

ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - The Globe and Mail

Dec 05, 2025
pulisher
Dec 05, 2025

Absci (NASDAQ:ABSI) Stock Price Up 10.8%Still a Buy? - MarketBeat

Dec 05, 2025
pulisher
Dec 05, 2025

Absci doses first volunteers in phase 1/2a trial of hair loss antibody - Investing.com Nigeria

Dec 05, 2025
pulisher
Dec 04, 2025

Absci doses first volunteers in phase 1/2a trial of hair loss antibody By Investing.com - Investing.com South Africa

Dec 04, 2025
pulisher
Dec 04, 2025

Absci Stock’s Financial Prospects: An In-Depth Analysis - StocksToTrade

Dec 04, 2025
pulisher
Dec 04, 2025

JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛

Dec 04, 2025
pulisher
Dec 04, 2025

Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial - simplywall.st

Dec 04, 2025
pulisher
Dec 04, 2025

Absci Corp. Strives for New Horizons Amid Financial Adjustments - timothysykes.com

Dec 04, 2025
pulisher
Dec 04, 2025

Absci announces first participants dosed in Phase 1/2a HEADLINE trial - TipRanks

Dec 04, 2025
pulisher
Dec 04, 2025

Absci (ABSI): Assessing Valuation as AI‑Designed Hair Loss Drug Enters First Phase 1/2a Trial - Yahoo Finance

Dec 04, 2025
pulisher
Dec 04, 2025

Absci Announces First Participants Dosed In Phase 1/2A Headline Trial - TradingView

Dec 04, 2025
pulisher
Dec 04, 2025

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - The Manila Times

Dec 04, 2025
pulisher
Dec 02, 2025

Will Absci Corporation stock deliver shareholder valueJuly 2025 Opening Moves & AI Optimized Trade Strategies - Newser

Dec 02, 2025
pulisher
Nov 28, 2025

Absci stock price target raised to $9 from $8 at Jones Trading By Investing.com - Investing.com South Africa

Nov 28, 2025
pulisher
Nov 28, 2025

Absci stock price target raised to $9 from $8 at Jones Trading - Investing.com Canada

Nov 28, 2025
pulisher
Nov 28, 2025

JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $9 - 富途牛牛

Nov 28, 2025
pulisher
Nov 26, 2025

Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛

Nov 26, 2025
pulisher
Nov 21, 2025

Absci Corp. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Performance - Markets Mojo

Nov 21, 2025
pulisher
Nov 21, 2025

Will Absci Corporation see short term momentumWeekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com

Nov 21, 2025
pulisher
Nov 19, 2025

How Absci Corporation stock benefits from tech adoptionJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Can trapped investors hope for a rebound in Absci CorporationGlobal Markets & Community Shared Stock Ideas - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

Can Absci Corporation stock double in next 5 yearsMarket Growth Report & Expert Approved Momentum Trade Ideas - newser.com

Nov 18, 2025
pulisher
Nov 17, 2025

Will Absci Corporation stock maintain growth storyJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com

Nov 17, 2025
pulisher
Nov 17, 2025

Absci Corp’s Earnings Call Highlights Strategic Growth - MSN

Nov 17, 2025
pulisher
Nov 16, 2025

Can Absci Corporation stock deliver sustainable ROE2025 Price Action Summary & Momentum Based Trading Ideas - newser.com

Nov 16, 2025
pulisher
Nov 16, 2025

Absci (ABSI) Valuation in Focus as Clinical Expansion and Partnership Efforts Gather Pace - Yahoo Finance

Nov 16, 2025
pulisher
Nov 16, 2025

Can Absci Corporation stock surprise with earnings upsideJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com

Nov 16, 2025
pulisher
Nov 15, 2025

Real time pattern detection on Absci Corporation stockPortfolio Update Summary & Proven Capital Preservation Methods - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

Absci Corporation Advances AI-Driven Therapeutics - MSN

Nov 15, 2025
pulisher
Nov 15, 2025

Absci’s Cash Reserves Bolster Future Financial Confidence - timothysykes.com

Nov 15, 2025
pulisher
Nov 15, 2025

Absci Corporation (NASDAQ:ABSI) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 15, 2025
pulisher
Nov 14, 2025

Absci Stock Takes a Leap: What’s Next? - StocksToTrade

Nov 14, 2025
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
Kapitalisierung:     |  Volumen (24h):